REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIa ANTIBODIES AND USES THEREOF
AssigneeNovartis AG
InventorsStefan EWERT, Yasser KHDER, Alexander KOCH
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.
Claims71
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A binding agent which specifically binds a target antibody that binds human FXI and/or FXIa within the catalytic domain, wherein the binding agent inhibits an anticoagulant activity of the target antibody,
- wherein the target antibody comprises (i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:
- 12 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:
- 23;
- or (ii) a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 14 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 25,
- wherein the binding agent is an antibody or antigen-binding fragment thereof comprising (1) a VH comprising complementarity determining regions HCDR1, HCDR2, and HCDR3 selected from those set forth in Table 2, and (2) a VL comprising complementarity determining regions LCDR1, LCDR2, and LCDR3 selected from those set forth in Table 2.
(canceled)
(canceled)
A pharmaceutical composition comprising the binding agent of 8.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An anti-idiotype antibody that specifically binds to an anti-FXI/FXIa antibody wherein the anti-FXI/FXIa antibody is NOV1401 or comprises the heavy chain variable region CDRs and light chain variable region CDRs of NOV1401.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of managing bleeding or bleeding risk in a patient treated or administered an anti-FXI/FXIa antibody, comprising the step of administering to the patient in need thereof, an anti-idiotype antibody of the anti-FXI/FXIa antibody, wherein the anti-idiotype specifically binds to the anti-FXI/FXIa antibody and blocks the anti-FXI/FXIa antibody from binding to FXI/FXIa, and wherein the anti-FXI/FXIa antibody is NOV1401 or comprises the heavy chain variable region CDRs and light chain variable region CDRs of NOV1401.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.